< PREVIOUS BOOTH NEXT BOOTH >
Madrigal Logo
Rezdiffra Banner Image
917-488-8859
Email Us
Visit Website
rezdiffra-tablet-bottles

Click to view our HCP Leave Behind Brochure

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH.

For more information, visit www.madrigalpharma.com.

About Rezdiffra

Product website:
https://www.rezdiffrahcp.com

Prescribing Information:
https://www.madrigalpharma.com/Rezdiffra-USPI

Questions?

Contact: Lori McMahon
Email: lmcmahon@madrigalpharma.com
Phone: 516-852-0628

Contact: Neelu Miglani
Email: nmiglani@madrigalpharma.com
Phone: 917-488-8859

  • This field is hidden when viewing the form
  • This field is for validation purposes and should be left unchanged.
< PREVIOUS BOOTH NEXT BOOTH >

Connected Culture, Inc. @ All rights reserved.